AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 21, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb 21, 2019--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.

A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc. Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005135/en/

CONTACT: Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie@sternir.comMillendo Media Contact:

Betsy Yates

MacDougall

781-235-3094

byates@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Millendo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 02/21/2019 08:00 AM/DISC: 02/21/2019 08:01 AM

http://www.businesswire.com/news/home/20190221005135/en

All contents © copyright 2019 The Associated Press. All rights reserved.